

The demand for HIV Drugs Market is raised during the forecast period 2020-2027

Limited supply of ARVs from manufacturers and disruption of land & air transport services is expected to negatively impact the HIV drugs market

NE WIN SIVERS DRIVE, PROVINCE: -
PORTLAND, UNITED STATES,
September 28, 2021 /

EINPresswire.com/ -- Allied Market
Research recently published a report,
titled, "Global [HIV Drugs Market](#) By

Medication Class (Multi-class
Combination Drugs, Nucleoside
Reverse Transcriptase Inhibitors

(NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors): Opportunity Analysis and Industry Forecast, 2020–2027". As per the report, the global HIV drugs industry was pegged at \$30.89 billion in 2019, and is projected to reach \$36.49 billion by 2027, growing at a CAGR of 3.8% from 2020 to 2027.

“

HIV Drugs Market By
Medication Class (Multi-class
Combination Drugs,
Nucleoside Reverse
Transcriptase Inhibitors
(NRTIs), Non-nucleoside
Reverse Transcriptase
Inhibitors (NNRTIs)”

Allied Market Research

Drivers, restraints, and opportunities

Rise in number of HIV-infected patients across the globe, various initiatives taken by different government associations to raise awareness have boosted the growth of the global HIV drugs market. Moreover, advent of generic drugs that are cost effective and chemically identical to branded drugs supplemented the market growth. However, strict regulatory requirements for the approval and commercialization of HIV drugs hamper the

market. On the contrary, rise in number of products in the pipeline is expected to create lucrative opportunities for the market players in the future.

For Right Perspective and Competitive Insights, Get Sample Report at:



Covid-19 scenario:

Shutdown of land & air transport services, failure of suppliers to deliver ARVs on time, and limited access to health services within countries due to pandemic hampered the demand for HIV drugs.

Moreover, rescheduling of HIV treatment procedures has resulted in a backlog of patients in the future.

However, some governments have allowed reopening private clinics that treat HIV, given that they comply with the social distancing regulations.

The multi-class combination drugs segment to manifest the highest CAGR through 2027

By medication class, the multi-class combination drugs segment is expected to register the highest CAGR of 4.2% during the forecast period. Moreover, the segment held the largest share in 2019, accounting for nearly half of the global HIV drugs market, owing to increase in adoption of drugs from this medication class because of better results in the control of HIV & related coinfections and their ease in consumption & adherence. The report includes analysis of the other segments such as nucleoside reverse transcriptase inhibitors (NRTIS), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PIs), HIV integrase strand transfer inhibitors, and entry inhibitors - CCR5 co-receptor antagonist.

North America held the lion's share

By region, the market across North America held the largest share in 2019, contributing to nearly half of the market, owing to increase in the number of HIV-infected individuals, advancement in HIV treatment, and rise in government funding for R&D for drug manufacturing. However, the global HIV drugs market across Asia-Pacific is estimated to register the highest CAGR of 4.4% during the forecast period, due to expansion of healthcare budgets and increase in disposable income.

Interested to Procure the Data? Inquire here @ <https://www.alliedmarketresearch.com/purchase-enquiry/1867>

Major market players

Boehringer Ingelheim International GmbH

Pfizer Inc.

Merck & Co., Inc.

GalaxoSmithKline plc.

Gilead Sciences, Inc.

F. Hoffmann-La Roche Ltd.

Johnson & Johnson

AbbVie

Teva Pharmaceutical Industries Ltd.

Cipla

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:

<https://www.alliedmarketresearch.com/avenue/trial/starter>

Get more information: <https://www.alliedmarketresearch.com/library-access>

Trending Reports In Healthcare Industry:

- 1) [Pharmaceutical Drug Delivery Market](#)
- 2) [Oncology/Cancer Drugs Market](#)

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Analytics LLP

+1 503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/552493903>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.